Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials

Suman Bhattacharya, Gwen Fyfe, Robert J. Gray, Daniel J. Sargent

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Sensitivity analysis is an important statistical technique that assesses whether the results of phase III trials are robust and likely to be generalizable. Until recently, sensitivity analyses were rarely included in phase III trials, and they remain poorly understood by many oncologists. Sensitivity analyses are critical to understanding the strength of conclusions made in the primary analysis of a late-stage clinical trial. They examine the influence of protocol design errors, unintended biases, deviations from assumptions underlying statistical models, and any unanticipated treatment delivery or practice patterns on trial results. In trials with complex or subjective end points, they also allow an understanding of the extent to which a positive outcome is driven by a single, possibly subjective, and therefore biased, element of an end point. The purposes of this article are to explain how sensitivity analyses are performed, to discuss areas of a clinical trial where sensitivity analyses should focus, and to illuminate the importance of this technique in the rigorous evaluation of late-stage clinical trial data, using specific examples. This article focuses on late-stage trials that use progression-free survival or time to progression as their primary end point, because sensitivity analyses are particularly important in these cases for which the end point is potentially subject to bias. Three sources of potential bias are explored: assessment time, symptomatic (ie, nonradiologic) disease progression, and missing data. For each source of potential bias, case studies are presented to highlight the role that sensitivity analyses play in determining whether the trial's conclusions are robust.

Original languageEnglish (US)
Pages (from-to)5958-5964
Number of pages7
JournalJournal of Clinical Oncology
Volume27
Issue number35
DOIs
StatePublished - Dec 10 2009

Fingerprint

Disease-Free Survival
Clinical Trials
Statistical Models
Disease Progression
Therapeutics
Oncologists

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. / Bhattacharya, Suman; Fyfe, Gwen; Gray, Robert J.; Sargent, Daniel J.

In: Journal of Clinical Oncology, Vol. 27, No. 35, 10.12.2009, p. 5958-5964.

Research output: Contribution to journalArticle

Bhattacharya, Suman ; Fyfe, Gwen ; Gray, Robert J. ; Sargent, Daniel J. / Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 35. pp. 5958-5964.
@article{10ac96692f2448dfbc0de6d15d752ef1,
title = "Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials",
abstract = "Sensitivity analysis is an important statistical technique that assesses whether the results of phase III trials are robust and likely to be generalizable. Until recently, sensitivity analyses were rarely included in phase III trials, and they remain poorly understood by many oncologists. Sensitivity analyses are critical to understanding the strength of conclusions made in the primary analysis of a late-stage clinical trial. They examine the influence of protocol design errors, unintended biases, deviations from assumptions underlying statistical models, and any unanticipated treatment delivery or practice patterns on trial results. In trials with complex or subjective end points, they also allow an understanding of the extent to which a positive outcome is driven by a single, possibly subjective, and therefore biased, element of an end point. The purposes of this article are to explain how sensitivity analyses are performed, to discuss areas of a clinical trial where sensitivity analyses should focus, and to illuminate the importance of this technique in the rigorous evaluation of late-stage clinical trial data, using specific examples. This article focuses on late-stage trials that use progression-free survival or time to progression as their primary end point, because sensitivity analyses are particularly important in these cases for which the end point is potentially subject to bias. Three sources of potential bias are explored: assessment time, symptomatic (ie, nonradiologic) disease progression, and missing data. For each source of potential bias, case studies are presented to highlight the role that sensitivity analyses play in determining whether the trial's conclusions are robust.",
author = "Suman Bhattacharya and Gwen Fyfe and Gray, {Robert J.} and Sargent, {Daniel J.}",
year = "2009",
month = "12",
day = "10",
doi = "10.1200/JCO.2009.22.4329",
language = "English (US)",
volume = "27",
pages = "5958--5964",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "35",

}

TY - JOUR

T1 - Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials

AU - Bhattacharya, Suman

AU - Fyfe, Gwen

AU - Gray, Robert J.

AU - Sargent, Daniel J.

PY - 2009/12/10

Y1 - 2009/12/10

N2 - Sensitivity analysis is an important statistical technique that assesses whether the results of phase III trials are robust and likely to be generalizable. Until recently, sensitivity analyses were rarely included in phase III trials, and they remain poorly understood by many oncologists. Sensitivity analyses are critical to understanding the strength of conclusions made in the primary analysis of a late-stage clinical trial. They examine the influence of protocol design errors, unintended biases, deviations from assumptions underlying statistical models, and any unanticipated treatment delivery or practice patterns on trial results. In trials with complex or subjective end points, they also allow an understanding of the extent to which a positive outcome is driven by a single, possibly subjective, and therefore biased, element of an end point. The purposes of this article are to explain how sensitivity analyses are performed, to discuss areas of a clinical trial where sensitivity analyses should focus, and to illuminate the importance of this technique in the rigorous evaluation of late-stage clinical trial data, using specific examples. This article focuses on late-stage trials that use progression-free survival or time to progression as their primary end point, because sensitivity analyses are particularly important in these cases for which the end point is potentially subject to bias. Three sources of potential bias are explored: assessment time, symptomatic (ie, nonradiologic) disease progression, and missing data. For each source of potential bias, case studies are presented to highlight the role that sensitivity analyses play in determining whether the trial's conclusions are robust.

AB - Sensitivity analysis is an important statistical technique that assesses whether the results of phase III trials are robust and likely to be generalizable. Until recently, sensitivity analyses were rarely included in phase III trials, and they remain poorly understood by many oncologists. Sensitivity analyses are critical to understanding the strength of conclusions made in the primary analysis of a late-stage clinical trial. They examine the influence of protocol design errors, unintended biases, deviations from assumptions underlying statistical models, and any unanticipated treatment delivery or practice patterns on trial results. In trials with complex or subjective end points, they also allow an understanding of the extent to which a positive outcome is driven by a single, possibly subjective, and therefore biased, element of an end point. The purposes of this article are to explain how sensitivity analyses are performed, to discuss areas of a clinical trial where sensitivity analyses should focus, and to illuminate the importance of this technique in the rigorous evaluation of late-stage clinical trial data, using specific examples. This article focuses on late-stage trials that use progression-free survival or time to progression as their primary end point, because sensitivity analyses are particularly important in these cases for which the end point is potentially subject to bias. Three sources of potential bias are explored: assessment time, symptomatic (ie, nonradiologic) disease progression, and missing data. For each source of potential bias, case studies are presented to highlight the role that sensitivity analyses play in determining whether the trial's conclusions are robust.

UR - http://www.scopus.com/inward/record.url?scp=73349111952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349111952&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.22.4329

DO - 10.1200/JCO.2009.22.4329

M3 - Article

C2 - 19826121

AN - SCOPUS:73349111952

VL - 27

SP - 5958

EP - 5964

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 35

ER -